Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2018Cancer DiscoveryOpen Access

A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

HRHaley E. RamseyVanderbilt University Medical CenterMFMelissa A. FischerVanderbilt UniversityTLTaekyu LeeVanderbilt University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ramsey et al. (2018) studied this question.

synapsesocial.com/papers/69da8b7284371aa676a3d5d8https://doi.org/10.1158/2159-8290.cd-18-0140
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Expression of p53, Bcl-2 and Ras Oncoproteins and Apoptosis Levels in Acute Leukaemias and Myelodysplastic Syndromes2001 · 36 citations
  2. 2Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1–expressing myeloma cells2011 · 137 citations
  3. 3Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)2015 · 116 citations